Edgewise Therapeutics

With your help, participating in clinical research can be easier for the person you care about with Becker. Explore Becker research here: beckergcstudy.com.

At Edgewise, we’re bringing our unique expertise and singular focus on muscle science to develop novel therapeutics for serious skeletal and cardiac muscle diseases – with determination, integrity and a strong commitment to patients. Join our movement in muscle. We’re a team of dedicated scientists working every single day on a new generation of revolutionary therapeutics, in Boulder and Beyond. Learn more about our mission here: edgewisetx.com/. #EdgewiseTherapeutics #Becker #BeckerMD #Duchenne #HCM

A significant number of people who have Becker muscular dystrophy need assistive mobility devices in their 40's. Mobility devices like power wheelchairs and standing frames can help those affected maintain independence and continue to do everyday activities. "There are advantages to the power chair. It’s brought me so much independence. I never thought a power chair would mean this much.” Mike, living with Becker To learn more, visit https://lnkd.in/e54DEHAg. #BeckerMD #BeckerMuscularDystrophy

We’re proud to support Parent Project Muscular Dystrophy to enhance the lives of those living with Duchenne and Becker. We celebrate alongside the community in acknowledging all the bold efforts PPMD has tirelessly fought for over the last 30 years. The organization has been instrumental in advancing care and treatments for the Duchenne and Becker community, from championing the groundbreaking MDA Care ACT, to developing the Duchenne Draft Guidance for Industry to pushing forward newborn screening. PPMD has been at the forefront of many innovative policies and priorities that have had a lasting impact on accelerating drug development for rare disease. But the magic is in the small things, the one-on-one dialogue staff has with a newly diagnosed Duchenne family, or those going through a tough transition with their child or just a rough patch. PPMD continues to grow and adapt to the ever-changing care landscape and we are forever grateful.

We are honored to be Colorado BioScience Association's 2024 Company of the Year! We are proud to be part of Colorado's thriving biotech community and leaders in muscle disease science.

We're excited to be at #AHA2024 and connecting with others in the cardiovascular community. Join us during the scientific poster session to learn about EDG-7500 in a non-obstructive HCM preclinical model. We're also hosting a meeting with our CIRRUS-HCM clinical trial investigators to provide information on this important program.

Access new research and a clinical study in Becker Muscular Dystrophy (BMD): beckergcstudy.com/. – Acceda a nuevas investigaciones y a un estudio clínico sobre la distrofia muscular de Becker (BMD)

We attended the Action Duchenne Conference in the UK! The annual international conference brings together biopharmaceutical companies, families, and more for two days of networking, science, and valuable insight. We're proud to sponsor an event that empowers and supports the Duchenne and Becker communities. #ActionDuchenne #EdgewiseTherapeutics #Duchenne #Becker

Our regulatory team provides critical regulatory guidance for our non-clinical, clinical, and CMC/quality activities, which ultimately enables our clinical trials of novel therapeutics to advance in patients with serious muscle diseases like hypertrophic cardiomyopathy and muscular dystrophies. Hear from Melissa King, Director, Regulatory CMC, on what it's like working alongside her team at Edgewise Therapeutics. #TeamSpotlight #CompanyCulture #EdgewiseTherapeutics